AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
High-Sensitivity C-Reactive Protein as a Cardiovascular Risk Factor in Cardiovascular-Kidney-Metabolic Syndrome, Independent of Low-Density Lipoprotein Cholesterol Level
By Ren X, Wang Z, Xiang J et al.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome integrates metabolic dysfunction, kidney impairment, and cardiovascular risk, yet systemic inflammation may independently drive CKM-related cardiovascular complications. High-sensitivity C-reactive protein (hsCRP) is widely used in clinical practice as a robust marker of systemic inflammation and has been established as an indicator of residual inflammatory risk. Whether hsCRP captures residual inflammatory risk within the CKM framework remains unclear. Methods: Among 102,170 UK Biobank participants free of baseline CVD, CKM stages (0-3) were defined using demographic, metabolic, and clinical parameters. Cox proportional hazards models examined hsCRP associations with eight incident outcomes including overall CVD, coronary heart disease (CHD), heart failure (HF), stroke, atrial fibrillation (AF), peripheral artery disease (PAD), cardiovascular death, and all-cause death. Joint LDL-C/hsCRP analyses evaluated residual inflammatory risk. Mediation analyses were used to quantify the contributions of multiple intermediate pathways, and proteomic analyses were performed to identify molecular mediators. Results: Higher hsCRP independently predicted all CVD outcomes. Participants in the highest hsCRP quartile (Q4) had significantly increased hazards (HR; 95% CI) for CVD (1.238; 1.187-1.292), CHD (1.255; 1.181-1.334), stroke (1.150; 1.059-1.250), HF (1.472; 1.332-1.625), AF (1.139; 1.063-1.221), PAD (1.496; 1.356-1.650), all-cause death (1.532; 1.449-1.620) and cardiovascular death (1.364; 1.164-1.599). Among low-LDL-C participants, elevated hsCRP remained associated with higher CVD risk (HR 1.126; 95% CI 1.022-1.241), supporting hsCRP as a marker of residual inflammatory risk beyond lipid burden. Associations were consistent across chronic kidney disease (CKD), diabetes, and obesity strata. Estimated glomerular filtration rate (eGFR) decline mediated 13.7% of the hsCRP-CVD association overall (9.3% in Stage 2; 29.4% in Stage 3). Proteomic analyses implicated PLAUR, GDF15, and IGFBP4 as candidate molecular mediators. Conclusions: hsCRP is an independent cardiovascular risk marker in CKM populations, extending residual inflammatory risk beyond lipid-controlled CVD. Renal dysfunction is a key mediating pathway, and proteomic findings highlight molecular targets for anti-inflammatory prevention strategies in CKM.